---
title: Diagnose Parkinsons disease with colonoscopy
nct_id: NCT07204652
status: RECRUITING
sponsor: CND Life Sciences
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07204652"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07204652"
last_fetched: "2026-05-10T14:08:05.145Z"
source: "Parkinson's Pathways (curated)"
---
# Diagnose Parkinsons disease with colonoscopy

**Goal (in five words):** Diagnose Parkinsons disease with colonoscopy

**Official Title:** Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders

**Trial ID:** [NCT07204652](https://clinicaltrials.gov/study/NCT07204652)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** CND Life Sciences
- **Target Enrollment:** 20 participants
- **Start Date:** 2025-09-03
- **Completion Date:** 2028-09
- **Conditions:** PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism, Parkinson Disease
- **Interventions:** No Intervention: Observational Cohort
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to see whether phosphorylated alpha-synuclein, the abnormal form of the protein linked to Parkinson's, can be detected in routine colon biopsies and help diagnose Parkinson's disease and related disorders. During a routine colonoscopy small tissue samples are taken and tested for phosphorylated alpha-synuclein, the disease-related protein that can accumulate in gut nerve cells, so researchers can learn if gut testing could support diagnosis without changing Parkinson's medications. They are looking for adults 40 to 99 with a confirmed Parkinson's diagnosis by UKPDS Brain Bank Criteria who are already scheduled for routine colonoscopy, excluding people on anticoagulants (single-agent aspirin up to 325 mg or clopidogrel 75 mg may be allowed), or with colon cancer, recent GI illness or surgery, pregnancy, or significant cognitive or decisional impairment.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 99 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Adults 40 to 99 years of age
* Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria
* Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases

Exclusion Criteria:

* Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)
* History of colon cancer
* Recent gastrointestinal illness or surgical procedures
* Pregnant or planning to become pregnant before the scheduled colonoscopy
* Significant cognitive impairment, as determined by study investigators
* Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes
```

## Locations (1)

- Oregon Health & Science University, Portland, Oregon, United States _(45.5234, -122.6762)_
  - Magda Armendariz Sullivan — (CONTACT) — 503-501-8478 — armendam@ohsu.edu
  - Sarah Diamond, MD — (SUB_INVESTIGATOR)

## Central Contacts

- Magda Armendariz Sullivan — (CONTACT) — 503-501-8478 — armendam@ohsu.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07204652*  
*HTML version: https://parkinsonspathways.com/trial/NCT07204652*  
*Source data: https://clinicaltrials.gov/study/NCT07204652*